Replimmune’s new melanoma drug just got a hard stop from the FDA, and it wasn’t your usual paperwork drama. The agency’s top cancer boss, Rick Pazdur, personally stepped in to reject the drug, leaving even some FDA insiders surprised. The stock tanked 75% and the company’s scrambling for answers. Apparently, the trial design didn’t fly—regulators said they couldn’t tell if the drug or its combo partner was doing the heavy lifting. Drama! #Health #BodyHealth #FDA